August 11th 2025
NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100, a preservation-free formulation of intravenous ketamine for suicidal ideation in depression.
Meeting the Mental Health Challenge of the COVID-19 Pandemic
April 24th 2020The public is gripped by fear of COVID-19 and by worry over whether the health system will be able to treat them or their loved ones should they become ill. Consequently, clinical and public health efforts have focused on acute medical care needs of those who are severely affected, while containing the virus’s spread in the population.
Read More
The New Game of Microbiology Clue: The Who, When, Where, and Why of the Novel Coronavirus
March 16th 2020Psychiatrists must have a basic understanding of the pathophysiology of coronaviruses in order to be able to accurately explain and discuss those issues with their patients, especially as mental health ramifications are expected.
Read More
Daylight Savings Time: Frequently Asked Questions and Answers for Psychiatrists
March 10th 2020There are people who insist the one-hour change causes havoc on their systems and schedules. Is there any scientific foundation to this claim? Let us examine some common questions, concerns, and myths.
Read More
A Clinician’s Brief Guide to Chronotherapy for Affective Disorders
March 5th 2020Chronotherapy presents a unique tool to add to the armamentarium of available modalities for management of non-seasonal depression. Clinicians should be familiar with its application and be able to implement it in recalcitrant sufferers.
Read More